文献速递中枢神经肿瘤放疗头颈部肿瘤放疗

贝伐珠单抗单药治疗鼻咽癌放射性脑坏死疗效的临床预测变量

Clinical Variables for Prediction of the Therapeutic Effects of Bevacizumab Monotherapy in Nasopharyngeal Carcinoma Patients With Radiation-Induced Brain Necrosis.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-11-21

本回顾性研究纳入50例鼻咽癌放疗后放射性脑坏死并接受贝伐珠单抗单药治疗、随访6个月的患者,基于脑MRI评估脑水肿体积变化。贝伐珠单抗治疗结束时T2-FLAIR所示病灶体积中位下降72.6%(四分位距34.5%–89.5%,P<.001),76.0%患者有效;随机森林模型提示颞叶最大放疗剂量是疗效的高度排名预测因子。

要点

  • 贝伐珠单抗治疗结束时放射性脑坏死体积中位下降72.6%,76.0%患者达有效反应。
  • 随机森林模型提示颞叶最大放疗剂量(Dmax)是贝伐珠单抗疗效的高度排名预测因子。
  • 放疗至贝伐珠单抗治疗间隔及放疗至放射性脑坏死确诊间隔是坏死复发的高度排名预测因子。

核心结论

  • 贝伐珠单抗可能对颞叶最大放疗剂量较低的患者更有效。
  • 采用随机森林模型可建立放射性脑坏死患者贝伐珠单抗疗效的预测模型。

研究设计与样本

  • 回顾性研究,纳入50例鼻咽癌放疗后诊断放射性脑坏死并接受贝伐珠单抗治疗、随访6个月的患者。
  • 基于脑磁共振成像评估贝伐珠单抗给药前、给药后、3个月及6个月随访时的脑水肿体积。
  • 对15例患者采用酶联免疫吸附试验测定基线血清血管内皮生长因子水平,并建立随机森林模型进行统计分析。

主要发现

  • 贝伐珠单抗治疗结束时T2-FLAIR图像所示放射性脑坏死体积中位下降72.6%(四分位距34.5%–89.5%,P<.001)。
  • 38例有效患者中15例出现放射性脑坏死复发。

关键数值与推荐

  • 随机森林模型中颞叶最大放疗剂量(Dmax)是贝伐珠单抗疗效的高度排名预测因子。
  • 放疗至贝伐珠单抗治疗间隔、放疗至放射性脑坏死诊断间隔是贝伐珠单抗治疗后坏死复发的高度排名预测因子。

临床怎么用

  • 对鼻咽癌放疗后放射性脑坏死患者,可结合颞叶最大放疗剂量评估贝伐珠单抗治疗预期获益。
  • 对放疗至贝伐珠单抗治疗间隔及放疗至放射性脑坏死诊断间隔较长的患者,宜关注治疗后坏死复发风险并加强随访。

局限性

  • 本研究为回顾性研究,样本量为50例,仅15例测定基线血清血管内皮生长因子水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To identify the predictive and prognostic factors for a decrease or recurrence of brain edema in patients who developed radiation-induced brain necrosis (RN) after radiation therapy for nasopharyngeal carcinoma (NPC) and who received bevacizumab monotherapy. METHODS AND MATERIALS: This was a retrospective study. The charts of 50 patients who were diagnosed with RN after radiation therapy for NPC, treated with bevacizumab, and followed up for 6 months were reviewed. Clinical data of these patients were collected, and their brain edema volume before bevacizumab administration, after bevacizumab administration, at 3-month follow-up, and at 6-month follow-up was evaluated on the basis of brain magnetic resonance imaging findings. The baseline serum vascular endothelial growth factor levels of 15 patients were measured by enzyme-linked immunosorbent assay. A random forests model was developed for statistical analysis. RESULTS: The median percentage of decrease in RN volume shown on T2-weighted fluid-attenuated inversion recovery images at the end of bevacizumab therapy was 72.6% (interquartile range, 34.5% to 89.5%; P < .001). Twelve of these 50 patients (24.0%) did not have an effective response, and 38 patients (76.0%) showed an effective response after bevacizumab administration. Fifteen of the 38 patients showed RN recurrence. According to the random forests model the maximum radiation dose of the temporal lobe (Dmax of the temporal lobe) was a highly ranked predictor for the therapeutic effect of bevacizumab. The duration between radiation therapy and bevacizumab treatment and the duration between radiation therapy and RN diagnosis were highly ranked predictors for RN recurrence after bevacizumab treatment. CONCLUSIONS: Prediction models for the therapeutic effect of bevacizumab in RN patients were developed, using the random forests model. Bevacizumab might be more effective in patients with a lower maximum radiation dose to the temporal lobe.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Li Y, Huang X, Jiang J, et al. Clinical Variables for Prediction of the Therapeutic Effects of Bevacizumab Monotherapy in Nasopharyngeal Carcinoma Patients With Radiation-Induced Brain Necrosis. Int J Radiat Oncol Biol Phys. 2017. PMID: 29413276. doi:10.1016/j.ijrobp.2017.11.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。